King & Spalding Continues Expansion of Its FDA/Healthcare Practice With the Addition of Senior Advisors Beverly Lorell, M.D., and Kay Scanlan

25 July 2006

In the continuing expansion of its FDA/Healthcare practice, King & Spalding, a leading international law firm, announced today the addition of two senior advisors whose special expertise enhances the firm's practice serving pharmaceutical, medical device, biologics and food manufacturers on FDA and healthcare regulatory issues.

Beverly H. Lorell, M.D., who recently stepped down as vice president and Chief Medical and Technology Officer of Guidant Corporation, will specialize in the area of clinical trial design of studies for drugs, devices and biologics; review of pre-market submissions; recalls; and assessment of matters involving a risk to health. M. Kay Scanlan, an attorney, will specialize in reimbursement consulting primarily for the pharmaceutical and biotech industries. Both Dr. Lorell and Scanlan are based in the firm's Washington, D.C. office.

The arrival of Lorell and Scanlan brings to six the total number of lawyers and professionals the firm has added in the past year to its 27-member FDA/Healthcare practice.

"For our pharmaceutical, medical device and biotech clients, getting top-notch counsel at every stage of the product life cycle is key," said John Bentivoglio, co-head of King & Spalding's FDA/Healthcare practice. "Bev and Kay add another dimension in our ability to do that by bringing us their special skills in FDA medical, regulatory and reimbursement issues."

Dr. Lorell, an interventional cardiologist and former professor of medicine at Harvard Medical School, was a member of the Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee. She received her medical degree from Stanford University.

Scanlan formerly was a reimbursement consultant representing biotechnology, drug and medical device manufacturers. She was also an adjunct professor of law at her alma mater, the University of Maryland Law School, where she taught Medicare and Medicaid law, and previously served in the Office of General Counsel for CMS and as director of reimbursement strategy at Biogen Idec.

King & Spalding's Washington, D.C.-based FDA/Healthcare group comprises 27 attorneys and non-attorney professionals who focus on assisting drug, device and biologics manufacturers at every stage of the product life cycle. The group's lawyers have expertise on issues ranging from clinical development, to FDA approval, CMA coverage and reimbursement, post-market advertising and promotion and healthcare regulatory compliance issues.

King & Spalding's Washington, D.C., office employs more than 160 attorneys and non-lawyer professionals, including government relations specialists, trade consultants and policy advisors. These lawyers and professionals practice in a broad range of areas including antitrust, class-action and mass tort litigation, commercial disputes, corporate finance, corporate governance, environmental, FDA/healthcare, public policy and government advocacy, government investigations, international trade, mergers and acquisitions and tax, among others.

About King & Spalding LLP

King & Spalding LLP is an international law firm with more than 800 lawyers in Atlanta, Houston, London, New York and Washington, D.C. The firm represents half of the Fortune 100, and in a Corporate Counsel survey in September 2005 was ranked one of the top ten firms representing Fortune 250 companies overall. For additional information, visit www.kslaw.com.

Contact: Jessica Schnack King & Spalding Phone: (212) 556-2226 Email: Email Contact

SOURCE: King & Spalding

Source: marketwire

All trademarks and copyrighted information contained herein are the property of their respective owners.